About 1 in 20 people with melanoma have a strong family history of the disease. (sciencedaily.com)
In the Phase 1 trial, patients in the high dose group demonstrated improvement in motor function and they had a decreased need for supportive care compared to the natural history of the disease. (sciencedaily.com)
But what about people who don't have a strong familial history of the disease? (discovermagazine.com)